Validating InoCardia's WorkLoop Model To Support Discovery Safety Improvements

点击翻译按钮获取中文摘要

When drugs/chemicals are developed to treat a particular disease or for human use purposes they sometimes have side effects that cause damage to the heart. Occasionally these dangerous side effects are only recognised after the drug/chemical has been marketed & taken/used by thousands of people. This is a significant risk to human health & is costly to the pharmaceutical industry when a dangerous product is withdrawn from market. Although side effects of drugs can be caused by many things, one area of great concern is the effects of drugs on the force that heart muscle can produce during its role in pumping blood around the body. Many drugs developed to treat Cancer have a high risk of reducing the force of contraction of the heart, can lead to the development of heart failure & increased mortality. InoCardia has recently developed a successful heart contractility (inotropy) assessment assay (supported by InnovateUK & NC3R) which is now being adopted by the Pharma Industry to manage inotropy risk at the late pre-clinical stage of drug development. We aim to validate our highly predictive contractility assessment technology for use in the early chemistry phases of drug development and the ability to screen out the risk of causing contractility issues.